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Background: Parathyroid hormone-related protein (PTHrP) pro-
motes osteoclastogenesis by inhibiting expression of osteoprote-
gerin (OPG), a decoy receptor for the receptor activator of nuclear
factor kappa B (RANK), and by enhancing production of RANK
ligand (RANKL) by osteoblasts. However, little is known regarding
the role of PTHrP in regulating cementoblast-mediated osteoclas-
togenesis.
Methods: This study determined the impact of PTHrP on osteo-
clastogenesis using: 1) OCCM-30 (immortalized murine cemento-
blasts), 2) RAW 264.7 cells (murine myeloid cells), or 3) OCCM-30
plus RAW 264.7 cells. Cells were treated with PTHrP (1-34),
RANKL, or PTHrP and RANKL combined. Enzyme-linked immuno-
sorbent assays (ELISAs) for OPG and RANKL were performed on
media and cell lysates, and tartrate-resistant acid phosphatase
(TRAP) and mRNA detection for the osteoclast associated receptor
(OSCAR) were performed.
Results: The highest numbers of TRAP-positive cells and
cells expressing OSCAR were found in the RAW cell group treated
with either RANKL alone or RANKL and PTHrP. TRAP-positive
cells were fewer when OCCM cells were co-cultured with RAW,
but the greatest numbers were still with both PTHrP and RANKL.
OPG levels were highest from OCCM cells and PTHrP decreased
these levels. In contrast, RANKL levels were low in OCCM cell
lysates and PTHrP increased RANKL. In vivo studies also revealed
high osteoclastic activity surrounding developing teeth in mice
administered PTH.
Conclusions: These results demonstrate that PTHrP influences
the balance of OPG and RANKL production by cementoblasts, and
further indicate that this effect, in the context of surrounding cells,
might have a significant impact on osteoclastogenesis, root resorp-
tion, and tooth eruption. J Periodontol 2004;75:1247-1254.
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A
series of cellular and molecular
events operate to promote tooth
formation and subsequently erup-
tion into the oral cavity. Several systemic
and local factors are considered impor-
tant for inducing differentiation and
proliferation of various types of cells, pro-
moting development of teeth and sur-
rounding periodontal tissues, and creating
a pathway for tooth eruption.1
Parathyroid hormone-related protein
(PTHrP) is a local factor which has para-
crine and/or autocrine functions, including
controlling tissue and organ development,
differentiation, proliferation, and cell survi-
val via its interaction with the type I PTH/
PTHrP receptor (PTH-1R).2,3
The process of tooth eruption provides
a valuable physiological model to analyze
bone resorption/remodeling and its use
has revealed that PTHrP is essential for pro-
moting osteoclastogenesis and bone re-
sorption during tooth eruption.4-6 Mice or
humans with loss of PTHrP function have
tooth impaction,7 failure of eruption,8 and
fusion of cementum with surrounding
alveolar bone.6 Replacement of PTHrP
restores these defects in mice.4 During
early events of tooth development, PTHrP
is produced by cells of epithelial origin,
known as the stellate reticulum and by
Hertwig’s epithelial cells. Cells of mesen-
chymal origin in the area, follicle cells,
osteoblasts, and cementoblasts, produce
PTHrP but at much lower levels.9 PTH and
PTHrP share the same receptor, the G pro-
tein-coupled PTH-1R.2 These tooth-asso-
ciated cell types of mesenchymal origin
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also express the PTH-1R.5,10-12 The actions of PTHrP on
cells within the local environment, including follicle cells
and osteoblasts, result in the recruitment of precursors
of the monocyte-macrophage lineage to the site of bone
resorption, fusion of these cells into multinucleated
osteoclasts, consequent alveolar bone resorption, and
creation of the tooth eruption pathway.13,14
Osteoclastogenesis and bone resorption are regu-
lated by production of the TNF receptor-ligand family
members, osteoprotegerin (OPG) and receptor activator
of nuclear factor kappa B (NF-κB) ligand (RANKL) by
osteoblast/stromal cells.15 RANKL is both a membrane-
associated cytokine and a bone microenvironment-
associated soluble factor that binds to the receptor
activator of NF-κB (RANK) on osteoclast precursor cells
to promote osteoclastogenesis. OPG, a secreted glyco-
protein, acts as a decoy receptor by binding to RANKL,
and inhibiting osteoclastogenesis.16-18 As an osteotropic
factor, PTHrP promotes osteoclastogenesis by increas-
ing levels of RANKL and decreasing OPG in osteoblast/
stromal cells.19-21
In the tooth microenvironment, OPG is expressed by
follicle cells and is downregulated by PTHrP.1,13 Expres-
sion of OPG/RANKL mRNA has been detected in human
periodontal ligament cells (PDL) in culture22 and local-
ized in vivo by immunohistochemistry in ameloblasts,
odontoblasts, and dental pulp cells.23 Interestingly, root
resorption is an uncommon event that is considered
pathologic versus the physiological bone resorption
that normally occurs as part of bone remodeling. The
actions of PTHrP on cementoblasts and their role in
osteoclastogenesis or odontoclastogenesis is poorly
understood. The purpose of this study was to determine
the role of PTHrP in regulating the expression of OPG/
RANKL by cementoblasts and subsequently the pro-
motion of osteoclastogenesis. A better understand-
ing of the role of PTHrP–cementoblast interactions
during tooth eruption and periodontal development
will contribute to the design of clinical strategies to
address dysregulated tooth eruption, as well as peri-
odontal diseases.
MATERIALS AND METHODS
Cell Culture and Treatments
Two cell lines were used for these experiments. OCCM-
30 cells are an immortalized murine cementoblast cell
line previously described.24 The murine myeloid cell
line RAW 264.7 is an osteoclast mononuclear precursor
cell line. Cells were plated in triplicate as follows: OCCM
alone, RAW 264.7 alone, or coculture of OCCM + RAW
264.7, in 60 mm dishes or 12-well plates at densities
of 25,000 cells/cm2 for OCCM and 5,000 cells/cm2 for
RAW 264.7. After plating (day 0) cells were maintained
in Dulbecco’s modified Eagle medium (DMEM) plus
10% fetal bovine serum (FBS) containing 100 U/ml of
penicillin and 100 µg/ml streptomycin|| in a humidified
atmosphere of 5% CO2 at 37°C. On day 2, supernatants
were collected and all groups were switched to DMEM
5% FBS containing penicillin/streptomycin and treated
as follows: 1) no treatment (control), 2) RANKL (0.2
µg/ml),¶ 3) PTHrP 1-34 (0.1 µM),# and 4) RANKL (0.2
µg/ml) plus PTHrP 1-34 (0.1 µM). Treatments were
replaced on day 4 after the collection of supernatants.
In Vivo Experiments
Pregnant mice at 16 days of gestation (day 0, vaginal
plug date) were given daily subcutaneous injections of
either recombinant human PTH 1-34 (10 µg/day)# or
vehicle (0.9% sodium chloride) until delivery on day
19 according to a UCUCCA-approved protocol. PTH
1-34 and PTHrP 1-34 have similar osteoclast-inducing
biologic activity2 and can be used interchangeably in
this model of osteoclast induction. Maxillary first molar
segments were removed from offspring mice 3 days
after birth (day 22 of development). Specimens were
fixed in 10% neutral buffered formalin for 24 hours,
decalcified in 10% EDTA for 5 days at room tempera-
ture, dehydrated in ascending series of ethanol, embed-
ded in paraffin, and serial sagittal sections generated at
5 µm thickness.
TRAP Staining
Tartrate-resistant acid phosphatase (TRAP) stain was
performed on tissue sections from in vivo studies, follow-
ing instructions from a commercial leukocyte acid phos-
phatase assay system.** Briefly, slides were deparaffinized
in xylene; hydrated in serial ethanol; and incubated in a
solution containing diazotized fast garnet, napthol AS-
BI phosphate, acetate, and tartrate solution for 1 hour at
37°C, while protected from light. Sections were rinsed
in dH2O and counterstained with hematoxylin. Histomor-
phometric analysis was performed using a computer-
assisted program†† and analytic software‡‡ with a light
microscope. The following measurements were taken:
total linear perimeter of alveolar bone surface sur-
rounding the tooth germ and number of TRAP-positive
osteoclasts per mm of osseous perimeter. Results were
expressed as mean ± SEM of 14 samples for each group.
For in vitro studies, cells were plated in 12-well plates
and treated as described. After 5 days, cells were fixed in
citrate buffered acetone/formaldehyde for 1 minute. Stain-
ing for TRAP was performed following instructions from
a commercial leukocyte acid phosphatase kit** as de-
scribed above. TRAP-positive osteoclasts were quanti-
fied by counting the number of multinucleated red-stained
cells. Results were expressed as number of TRAP-positive
cells per well.
|| Invitrogen, Grand Island, NY.
¶ PeproTech, Rocky Hill, NJ.
# Bachem, Torrance, CA.
** Sigma, St. Louis, MO.
†† Image-Pro Plus 4.1, Media Cybernetics, Silver Spring, MD.
‡‡ SPOT RT Diagnostic Inst. 3.0, Sterling Heights, MI.
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Enzyme-Linked Immunosorbent Assay (ELISA)
for OPG and RANKL
Cells were seeded in 12-well plates and treated as
described above. Media were collected at days 2, 4, and
5 and frozen at −20°C. At day 5, cells were removed from
the plates by scraping in 1 ml lysis buffer (150 mM NaCl,
10 mM phosphate buffer pH 7, 1% NP40, 0.1% SDS, 1%
sodium deoxycholate), vortexed and centrifuged. Super-
natants were removed and transferred to new tubes, and
total protein concentration was measured according to
instructions from a Bradford-based protein assay.§§
An ELISA to detect OPG and RANKL was performed
from collected media on days 2, 4, 5 and from cell lysate
processed on day 5. For OPG levels, collected supernatant
and lysate were diluted 1:10. ELISAs were performed fol-
lowing the instructions from assay systems specifically
designed to measure these proteins|| || and results were nor-
malized to protein levels.
Real-Time PCR
Cells were plated in 60 mm dishes and treated as de-
scribed above. Total RNA was harvested from OCCM
alone, RAW alone, or OCCM + RAW cocultures for quan-
titative analysis of OSCAR gene expression by real-time
polymerase chain reaction (PCR).¶¶ Briefly, RNA was
isolated from 60 mm dishes using guanidinium isoth-
iocyanate25 and treated with the DNA-free DNAase
reagent system## to eliminate genomic DNA. One micro-
gram of total RNA was reverse transcribed to cDNA
using TaqMan reverse transcriptase reagents*** follow-
ing the manufacturer’s protocol using a thermal cycler.†††
Real-time PCR amplification reactions for GAPDH for
normalization were performed in 25 µl containing 1 µl
cDNA, 12.5 µl 2× TaqMan universal PCR master mix,
100 nM probe, and 100 nM primers. OSCAR reactions
were performed in 20 µl, containing 9 µl cDNA, 10 µl 2×
TaqMan universal PCR master mix, 100 nM probe, and
100 nM primers. The sequences of primers and probes
used were: OSCAR sense GGGCATGAGTTTTGCACTG
TAC-18′, antisense GGGCTGCACAGAGTCAATATACTG-
18′, FAM probe TTGCCACGCCTACGCG-5′. Amplification
conditions were 2 minutes at 50°C and 10 minutes at
95°C, then 40 cycles of denaturation at 95°C for 15 sec-
onds, and annealing at 60°C for 1 minute. To control for
variability in amplification due to differences in starting
cDNA concentrations, GAPDH primers and probe from a
commercial source*** were used as an internal standard.
Threshold cycle Ct, which correlates inversely with the
target mRNA levels, was measured as the cycle number
at which the reporter fluorescent emission increases above
a threshold level. The relative expression of target mRNA
was calculated from Ct values normalized to GAPDH.
Statistical Analysis
Assays were performed two or three times with simi-
lar results. All data were examined using analysis of
variance with a Bonferroni multiple comparisons post-
test using a biostatistical program‡‡‡ and significance
set at P <0.05.
RESULTS
TRAP Staining
Cell cultures at day 5 were evaluated for TRAP-positive
cells. OCCM cells alone did not stain for TRAP, regard-
less of treatment (Fig. 1). RAW cells treated with RANKL
alone or in combination with PTHrP had the highest num-
ber of TRAP-positive multinucleated osteoclasts (134.3 ±
5.5 and 141.3 ± 9.0 per well, respectively), while PTHrP
alone was not able to induce osteoclastogenesis of RAW
cells.
Untreated OCCM/RAW co-cultures did not have any
TRAP-positive multinucleated osteoclasts. When RANKL
was added to the coculture there was an increase in
TRAP-positive multinucleated osteoclasts (17 ± 1.5) but
much less than RAW cells alone treated with RANKL.
PTHrP treatment of cocultures resulted in few TRAP-
positive mononucleated osteoclasts; however, when cells
were treated with PTHrP in combination with RANKL
there was a significant increase in numbers of TRAP-
positive multinucleated osteoclasts (84.3 ± 8.6), but still
not as great as the number of positive cells in the RAW
cells cultured with RANKL.
Figure 1.
TRAP staining to detect multinucleated osteoclasts (red-stained
multinucleated cells) after 5 days of treatment with RANKL (0.2 µg/ml),
PTHrP (1-34) (0.1 µM), or a combination of RANKL and PTHrP.
*P <0.001 versus respective group control without treatment. Data
are presented as mean ± SEM of triplicate samples.
§§ DC Protein assay, Bio-Rad, Hercules, CA.
|| || Quantikine mouse OPG and RANKL kit assay systems, R & D Systems,
Minneapolis, MN.
¶¶ Prism 7700 Sequence Detector, Perkin Elmer/Applied Biosystems,
Foster City, CA.
## Ambion Inc., Austin, TX.
*** Applied Biosystems.
††† Peltier PTC-200, MJ Research, Inc., Watertown, MA.
‡‡‡ Instat 2.1 biostatistical program, GraphPad Software, San Diego, CA.
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Figure 3.
OPG levels were measured by ELISA in media collected on day 2, prior to
addition of treatments (A); day 4, prior to addition of treatments (B); and
day 5 (C). OCCM,RAW, and OCCM+RAW cells were treated with RANKL
(0.2µg/ml), PTHrP 1-34 (0.1µM), or RANKL+PTHrP on days 2 and 4.
OPG levels were not detected in media from RAW cells under any conditions
(data not shown). *P <0.05, †P <0.001 versus group control without
treatment.Data are expressed as mean ± SEM of triplicate cultures.
In vivo results support the in vitro findings. In a com-
plex tissue model during development where PTH was
administered for 3 days, an increase in the number of
TRAP-positive osteoclasts was found surrounding the
developing teeth of PTH-treated animals as compared
to vehicle-treated mice (Fig. 2). This increase in TRAP-
positive multinucleated cells was evident along the
perimeter of alveolar bone surrounding the developing
molar.
ELISA
OPG and RANKL levels were analyzed by ELISA in media
collected on days 2, 4, and 5, and in cell lysates from
day 5. OPG was produced in high levels in untreated
OCCM cells with levels increasing from day 2 to day 5
(Fig. 3), and all treatments significantly reduced levels.
Expression of OPG by OCCM cells treated with RANKL
was much lower in media on day 4 (4-fold lower) and
day 5 (8-fold lower) versus untreated OCCM on the cor-
responding day (Figs. 3B, 3C). PTHrP added to OCCM
decreased levels of OPG 5-fold on day 4 and 9-fold on
day 5. The combination of RANKL + PTHrP treatment
on OCCM cells resulted in a decrease in OPG levels, 11-
fold on day 4 (Fig. 3B) and 25-fold on day 5 (Fig. 3C)
when compared with untreated OCCM. OPG was not
detected in media from RAW cells alone or from RAW
cells treated with RANKL, PTHrP, or RANKL and PTHrP
(data not shown). The untreated co-culture of OCCM
and RAW cells exhibited significantly lower levels of
OPG in media when compared with OCCM alone. On
day 4, OPG levels in co-culture of OCCM and RAW
were 4-fold lower than OCCM alone and on day 5 were
18-fold lower. Levels of OPG in media with the addition
of RANKL or PTHrP were not significantly different com-
pared with the untreated group but the combination of
Figure 2.
TRAP staining was performed on sections of maxillary first molars of
neonatal mice whose mothers were injected with PTH 1-34 for 3 days
prior to birth (10 µg/day). PTH treated animals had increased numbers
of TRAP-positive osteoclasts on the osseous perimeter surrounding the
developing tooth germ. Numbers of TRAP-positive osteoclasts per mm
osseous perimeter are plotted with n = 14 mice/group. Data are
presented as mean ± SEM. *P <0.05 versus vehicle treatment.
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Figure 4.
RANKL levels were measured by ELISA from media collected on day 2,
prior to addition of treatments (A); day 4, prior to addition of treatments
(B); and day 5 (C). OCCM, RAW, and OCCM+RAW cells were treated
with RANKL (0.2µg/ml), PTHrP 1-34 (0.1µM), or RANKL+PTHrP on days
2 and 4. *P <0.05, †P <0.001 versus respective group control without
treatment. Data are expressed as mean ± SEM for triplicate samples.
RANKL and PTHrP significantly lowered OPG levels in
day 4 co-cultures.
In contrast to OPG, levels of RANKL in media from
untreated OCCM cells cultured alone displayed a trend
toward decreasing over time from day 2 to day 5 (Fig. 4).
RANKL levels were 5-fold higher at day 4 in media
from OCCM cells treated with RANKL versus untreated
(Fig. 4B), but this effect was not observed on day 5
(Fig. 4C). The addition of PTHrP did not significantly
increase RANKL in media from OCCM cells alone by
day 5 (Fig. 4C); however, the combination of RANKL and
PTHrP increased RANKL levels (5-fold) on day 5 in these
cell cultures.
Media from RAW cells alone contained measurable
RANKL on day 2 (2.8 ± 0.5) (Fig. 4A), and these levels
were increased with RANKL alone or the combination
of RANKL and PTHrP at day 5 (4-fold) compared to
untreated RAW cells (Fig. 4C).
In co-culture, RANKL levels in secreted media were
low for the untreated group on days 4 and 5, similar to
untreated OCCM and RAW cells alone (Figs. 4B and 4C).
RANKL treatment promoted an extremely significant
38-fold increase in RANKL levels on day 4 (Fig. 4B), but
this effect was diminished on day 5 (Fig. 4C) when com-
pared with control. Cells in co-culture treated with PTHrP
showed mild but not significant increases in RANKL on
day 4 and day 5 when compared to untreated co-cul-
tures, but the combination of RANKL with PTHrP pro-
moted a significant increase in these levels on day 4
(22-fold) with still significant but lower levels on day 5
(5-fold) (Figs. 4B and 4C).
Analysis of cell lysates at day 5 revealed that OCCM
cells contained high levels of OPG, which was unaffected
by treatment with RANKL, but was highly inhibited by
treatment with PTHrP or RANKL plus PTHrP (5-fold re-
duction) (Fig. 5A). In co-cultures (OCCM +RAW), the
level of OPG was significantly lower when compared to
OCCM alone and the effects of treatments were insignif-
icant. OPG was not detected in RAW cell lysates under
any condition (data not shown).
RANKL levels in untreated OCCM cell lysates were low
and were unaffected by addition of RANKL (Fig. 5B).
PTHrP or PTHrP with RANKL increased this level 9-fold
and 12-fold, respectively. RANKL levels were higher in
untreated RAW cells than untreated OCCM cells and the
addition of RANKL reduced RAW RANKL levels. RAW
cell co-cultures with untreated OCCM cells promoted an
increase of 12-fold in levels of RANKL in cell lysate when
compared to OCCM cells alone; however, all treatments
decreased levels of RANKL in cell lysates.
Real-Time PCR for OSCAR Gene Expression
Analysis of OSCAR gene expression quantification by
real-time PCR revealed increased OSCAR gene expres-
sion on RAW cells alone treated with RANKL (11-fold)
and RANKL combined with PTHrP (6-fold) compared to
untreated RAW cells (Fig. 5C). In co-culture, no signif-
icant changes of OSCAR gene expression were observed
with any treatments resulting in reduced OSCAR mRNA
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Figure 5.
OPG (A) and RANKL (B) levels were measured by ELISA in cell
lysates. OSCAR mRNA was measured by real-time PCR from cells
obtained on day 5 (C). OCCM, RAW, and OCCM + RAW cells were
treated with RANKL (0.2 µg/ml), PTHrP 1-34 (0.1 µM), or RANKL +
PTHrP. *P <0.05, †P <0.001 versus respective group control without
treatment. Data are expressed as mean ± SEM for triplicate
samples.
levels in treated co-cultures as compared to treated
RAW cell cultures alone.
DISCUSSION
OPG and RANKL are proteins that can be controlled by
a variety of factors, resulting in inhibition or promotion
of osteoclastogenesis.21 The expression of OPG and
RANKL and their involvement in osteoclastogenesis dur-
ing tooth development and eruption, as well as expres-
sion in periodontal tissues has been described.5,22,23,26-29
The present study extends these observations to the
identification and regulation of OPG and RANKL in
cementoblasts and the ability of PTHrP to alter levels of
OPG and RANKL and to affect osteoclastogenesis.
Results from the present study indicate that, similar to
osteoblastic cells, PTHrP is capable of regulating osteo-
clast formation via a balance between expression of OPG
and RANKL. Additionally, they demonstrate that cemen-
toblasts synthesize and secrete OPG and further inhibit
osteoclast formation in co-culture with osteoclast mono-
nuclear precursor cells, which suggests that cemento-
blasts may be responsible for maintaining lower levels
of osteoclastic activity at the root surface as compared
to the adjacent alveolar bone. In this study, PTHrP acted
on cementoblasts to decrease levels of OPG and pro-
moted the development of TRAP-positive osteoclasts in
co-culture alone and in combination with RANKL. These
findings suggest that the protective role of OPG against
osteoclastic mediated alveolar bone resorption in perio-
dontal tissues and perhaps root resorption may be dys-
regulated by PTHrP and/or other factors that regulate
the ratio of OPG/RANKL in periodontal tissues, and that
cementoblasts may be active participants in this action.
Studies have shown RANKL mRNA and protein
expression in the cytoplasm of osteoblasts, osteocytes,
osteoclasts, and periodontal ligament fibroblasts,22,30
and also in the rough endoplasmic reticulum (RER).31
Studies have also shown that expression of RANKL
mRNA can be upregulated in response to osteotropic
factors such as PTHrP.32,33 Cementoblasts are target
cells for PTHrP10 and our results now show that cemen-
toblasts respond to PTHrP treatment by increasing syn-
thesis of cell-associated RANKL.
The importance of PTHrP in osteoclastogenesis was
evident from results of studies with PTHrP knockout
mice, where impaction of tooth germs and failure of
tooth eruption were found.6,14 Replacement of PTHrP
promoted differentiation of precursor cells into TRAP-
positive osteoclasts, thus restoring bone resorption and
subsequently tooth eruption.4 Our results with cemen-
toblasts in co-culture with mononuclear precursor cells
indicate that root surface cells respond to PTHrP in a
similar fashion as adjacent osteoblasts. Added PTHrP
promoted the differentiation of TRAP-positive multinu-
cleated osteoclasts by inhibiting OPG and increasing
RANKL levels. Additional soluble RANKL in this system
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was also enough to promote TRAP-positive cells to a
similar extent as that induced by PTHrP. In contrast to
our results, Fuller et al. reported no additive effect with
the combination of PTHrP and RANKL on osteoblasts,34
but in the present study with cementoblasts, this com-
bination significantly increased the number of TRAP-
positive multinucleated osteoclasts in co-culture.
It is well accepted that mononuclear precursor cells are
not direct targets of PTHrP, but express the membrane-
bound signaling receptor RANK that interacts with RANKL
produced by osteoblast/stromal cells in response to PTHrP.
This indirect action of PTHrP induces the differentiation
of osteoclastic precursors into multinucleated osteo-
clasts.12,32,34 Some studies found RANKL mRNA and
protein along the ruffled border of mature osteoclasts,
and expression correlated with osteoclastic activation
and survival.30,31 In the present study, RANKL levels in
cell lysates were detected in untreated RAW osteoclastic
precursor cells but did not appear to promote osteoclast
activation since there was no TRAP stain detected in
untreated RAW cells. Previous studies reported TRAP-
positive cells when pre-osteoclasts were cultured on den-
tin slices and incubated with RANKL.27,32,35 These results
suggest that RANKL can replace osteoblast/stromal cells
in the induction of osteoclastogenesis. In agreement with
this, addition of soluble RANKL promoted maximum dif-
ferentiation of mononuclear precursor cells to TRAP-pos-
itive multinucleated osteoclasts even in the absence of
cementoblasts. PTHrP alone did not promote osteoclas-
togenesis of these cells suggesting that cementoblasts
are necessary to promote RANKL production in response
to PTHrP. On the other hand, the direct effect of soluble
RANKL on osteoclastogenesis was diminished by the
presence of cementoblasts in co-culture, most likely re-
lated to the ability of OPG to inhibit osteoclastogenesis.
Recently, a new member of the leukocyte receptor
complex (LRC)-encoded family was identified and found
to be expressed exclusively in osteoclasts.36,37 Named
OSCAR, for osteoclast associated receptor, it is ex-
pressed in bone marrow derived osteoclasts, RAW 264.7
derived osteoclasts, and in whole bone. Its putative ligand,
OSCAR-L, is expressed primarily in osteoblasts/stromal
cells.36 Virtually nothing has been reported about the
role of PTHrP in the induction of OSCAR. Our study sug-
gests that RANKL can induce differentiation and activa-
tion of mononuclear precursor cells into TRAP-positive
osteoclasts that express the late differentiation gene
OSCAR. Since the co-cultures demonstrated OSCAR
gene expression that was not increased with treatments,
it is possible that cementoblasts may restrict OSCAR gene
expression even with RANKL and PTHrP stimulation.
In conclusion, results from this investigation show for
the first time that PTHrP regulates OPG/RANKL levels
in cementoblasts in a manner comparable to that re-
ported for other cell types within the oral environment,
including follicle cells and osteoblast/stromal cells. In
periodontal tissues, maintenance of OPG levels by ce-
mentoblasts may be essential to protect the root surface
from resorption.
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